Swedish Orphan Current Valuation vs. Price To Earning

B6E Stock  EUR 26.44  0.04  0.15%   
Considering Swedish Orphan's profitability and operating efficiency indicators, Swedish Orphan Biovitrum may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Swedish Orphan's ability to earn profits and add value for shareholders.
For Swedish Orphan profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Swedish Orphan to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Swedish Orphan Biovitrum utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Swedish Orphan's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Swedish Orphan Biovitrum over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Swedish Orphan's value and its price as these two are different measures arrived at by different means. Investors typically determine if Swedish Orphan is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Swedish Orphan's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Swedish Orphan Biovitrum Price To Earning vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Swedish Orphan's current stock value. Our valuation model uses many indicators to compare Swedish Orphan value to that of its competitors to determine the firm's financial worth.
Swedish Orphan Biovitrum is rated below average in current valuation category among its peers. It is rated below average in price to earning category among its peers . The ratio of Current Valuation to Price To Earning for Swedish Orphan Biovitrum is about  365,144,465 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Swedish Orphan's earnings, one of the primary drivers of an investment's value.

Swedish Current Valuation vs. Competition

Swedish Orphan Biovitrum is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers - Specialty & Generic industry is currently estimated at about 240.92 Billion. Swedish Orphan holds roughly 6.67 Billion in current valuation claiming about 2.77% of equities under Drug Manufacturers - Specialty & Generic industry.

Swedish Price To Earning vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Swedish Orphan

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
6.67 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Swedish Orphan

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
18.28 X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Swedish Price To Earning Comparison

Swedish Orphan is rated below average in price to earning category among its peers.

Swedish Orphan Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Swedish Orphan, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Swedish Orphan will eventually generate negative long term returns. The profitability progress is the general direction of Swedish Orphan's change in net profit over the period of time. It can combine multiple indicators of Swedish Orphan, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. SWEDISH ORPHAN is traded on Frankfurt Stock Exchange in Germany.

Swedish Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Swedish Orphan. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Swedish Orphan position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Swedish Orphan's important profitability drivers and their relationship over time.

Use Swedish Orphan in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Swedish Orphan position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Swedish Orphan will appreciate offsetting losses from the drop in the long position's value.

Swedish Orphan Pair Trading

Swedish Orphan Biovitrum Pair Trading Analysis

The ability to find closely correlated positions to Swedish Orphan could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Swedish Orphan when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Swedish Orphan - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Swedish Orphan Biovitrum to buy it.
The correlation of Swedish Orphan is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Swedish Orphan moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Swedish Orphan Biovitrum moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Swedish Orphan can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Swedish Orphan position

In addition to having Swedish Orphan in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Precious Metals Thematic Idea Now

Precious Metals
Precious Metals Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Precious Metals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Swedish Stock

To fully project Swedish Orphan's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Swedish Orphan Biovitrum at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Swedish Orphan's income statement, its balance sheet, and the statement of cash flows.
Potential Swedish Orphan investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Swedish Orphan investors may work on each financial statement separately, they are all related. The changes in Swedish Orphan's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Swedish Orphan's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.